Search results
In accordance with 35 U.S.C. § 287 (a), the following table used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product; additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive and other ...
Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling. This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only.
Notes on specific products. * in the US approved under the brand name Xultophy® 100/3.6. ** in the US called NovoLog®. *** in the US spelt Novoeight®. **** in the US approved under the name of REBINYN®. Overview of our diabetes medications, obesity medication and also medicines within haemophilia, human growth hormone and hormone ...
Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page
FIASP® (insulin aspart) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 ——— INDICATIONS AND USAGE ———. FIASP® is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus (1). ———DOSAGE AND ADMINISTRATION———.
Jun 4, 2021 · Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information
The Novo Nordisk Way describes the values and behaviors that guide everything we do. It is rooted in the principles and vision of our founders who set out on an ambitious journey to drive change for patients with diabetes in 1923. Today, we are thousands of colleagues applying the same passion, skills, and commitment to our purpose of driving ...
